false
0001505497
0001505497
2026-08-07
2026-08-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report: August 7, 2026
(Date of earliest event reported)
BIORESTORATIVE
THERAPIES, INC.
(Exact
Name of Registrant as Specified in Charter)
| Nevada |
|
001-37603 |
|
30-1341024 |
(State or Other Jurisdiction of
Incorporation) |
|
(Commission
File No.) |
|
(IRS Employer
Identification Number) |
| 40
Marcus Drive, Melville, New York |
|
11747 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (631) 760-8100
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.0001 par value |
|
BRTX |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
On August 7, 2026, BioRestorative Therapies, Inc. (the “Company”) suspended, effective immediately,
all orders and shipments of its biocosmeceutical product lines, consisting of its ExoCR products and its BioX products, pending a business
review and regulatory assessment. The Company has not made a decision to discontinue these product lines.
The
Company is conducting a review of the documentation, sourcing, and regulatory status associated with these products.
Forward-Looking
Statements
This
Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company’s business review
and regulatory assessment, the potential outcomes of that review, and the status of the Company’s biocosmeceutical product lines.
These statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual
results to differ materially, including the outcome of the review, the Company’s ability to resume sales of the affected product
lines, the costs associated with the suspension, the Company’s need for additional capital, and the risk factors described in the
Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its subsequent filings with the Securities and Exchange
Commission. The Company undertakes no obligation to update any forward-looking statement except as required by law.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
| 104 |
Cover Page Interactive Data File (embedded within the Inline
XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| BIORESTORATIVE
THERAPIES, INC. |
|
| |
|
|
| Date: |
August
14, 2026 |
|
| |
|
|
| By: |
/s/
Katharyn Field |
|
| Name: |
Katharyn
Field |
|
| Title: |
Director,
Chief Executive Officer, President and Interim Chief Financial Officer |
|
